INMB vs LRCX · rev $50.0K vs P/E 71, rev $23.23B
INmune Bio Inc (INMB) versus Lam Research Corp (LRCX) — a side-by-side from cached financials, not a winner call.
INmune Bio Inc (INMB) is a biotechnology company listed on US.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
Latest reported INMB revenue for 2025-09-30 was $50.0K. Net income was -$6.5M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. INMB currently screens at market cap $33.5M.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
INMB currently screens at market cap $33.5M. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Not investment advice. Open the INMB and LRCX stock pages for the full models.
Not investment advice.